Oxolinic acid in urinary tract infection: a multi-centre trial.
A single-blind trial of oxolinic acid (750 mg. twice-daily for 14 days) and ampicillin (500 mg. 3-times daily for 14 days) in 60 cases with urinary tract symptoms showed superior results with oxolinic acid: 94% of pathogens were sensitive to oxolinic acid and 69% were sensitive to ampicillin. Sympotomatic relief and bacterial eradication occurred earlier in the oxolinic acid group.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004926:Escherichia coli / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000188:drug therapy; D005194:Family Practice; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010093:Oxolinic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D010403:Penicillin Resistance; D012008:Recurrence; D013997:Time Factors; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000667:Ampicillin; D010093:Oxolinic Acid